Management of adult mastocytosis

Bibliography

• Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors, WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon; 2008. p. 54-63
   Google Scholar
• Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53
   PubMed Web of Science ®Google Scholar
• Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:1157-68
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-6
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol 2010;125:1269-78
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2013; published online 3 August 2013, doi:10.1016/j.jaci.2013.06.020
   Web of Science ®Google Scholar
• Alvarez-Twose I, Bonadonna P, Matito A, et al. Systemic mastocytosis as a risk factor for severe hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol 2013;131:614-15
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, et al. Current state of biology and diagnosis of clonal mast cell diseases in adults. Int J Lab Hematol 2012;34:445-60
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Matito A, Sanchez-Munoz L, et al. Contribution of highly sensitive diagnostic methods to the diagnosis of systemic mastocytosis in the absence of skin lesions. Allergy 2012;67:1190-1
   PubMed Web of Science ®Google Scholar
• Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-21
   PubMed Web of Science ®Google Scholar
• Kudo H, Morinaga S, Shimosato Y, et al. Solitary mast cell tumor of the lung. Cancer 1988;61:2089-94
   PubMed Web of Science ®Google Scholar
• Georgin-Lavialle S, Aguilar C, Guieze R, et al. Mast cell sarcoma: a rare and aggressive entity–report of two cases and review of the literature. J Clin Oncol 2013;31:e90-7
   PubMed Web of Science ®Google Scholar
• Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5
   PubMed Web of Science ®Google Scholar
• Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125:719-26
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Gonzalez P, Morgado JM, et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012;30:e126-9
   PubMed Web of Science ®Google Scholar
• Morgado JM, Perbellini O, Johnson RC, et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013; published online 4 July 2013, doi:10.1111/his.12221
   PubMed Web of Science ®Google Scholar
• Akin C, Scott LM, Metcalfe DD. Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case? Leuk Res 2001;25:635-8
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Tsujimura T, Jippo T, Kasugai T. Regulation of mast cell development by c-kit receptor and its ligand. Acta Histochem Cytochem 1994;27:17-22
   Web of Science ®Google Scholar
• Galli SJ, Tsai M, Wershil BK, et al. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 1995;107:51-3
   PubMed Web of Science ®Google Scholar
• Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-4
   PubMed Web of Science ®Google Scholar
• Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-14
   PubMed Web of Science ®Google Scholar
• Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30
   PubMed Web of Science ®Google Scholar
• Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-7
   PubMed Web of Science ®Google Scholar
• Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-92
   PubMed Web of Science ®Google Scholar
• Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-4
   PubMed Web of Science ®Google Scholar
• Mital A, Piskorz A, Lewandowski K, et al. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011;86:531-5
   PubMed Web of Science ®Google Scholar
• Zhang LY, Smith ML, Schultheis B, et al. A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8
   PubMed Web of Science ®Google Scholar
• Galli SJ, Dvorak AM, Dvorak HF. Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy 1984;34:1-141
   PubMedGoogle Scholar
• Katz HR, Raizman MB, Gartner CS, et al. Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J Immunol 1991;148:868-71
   Web of Science ®Google Scholar
• Nuñez R, Escribano L, Schernthaner G, et al. Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol 2002;120:257-65
   Web of Science ®Google Scholar
• Varadaradjalou S, Féger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003;33:899-906
   PubMed Web of Science ®Google Scholar
• Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, et al. Human mast cell activation by Staphylococcus aureus: IL-8 and TNF-{alpha} release and the role of toll-like receptor 2 and CD48 molecules. Infect Immun 2008;76:4489-97
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Narita S, Lambert KC, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol 2007;44:1977-85
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Spanos C, Pang XZ, et al. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 1995;136:5745-50
   PubMed Web of Science ®Google Scholar
• Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis [see comments]. J Allergy Clin Immunol 1989;83:866-70
   PubMed Web of Science ®Google Scholar
• Metcalfe DD. The treatment of mastocytosis: an overview. J Invest Dermatol 1991;96:55S-6S
   Web of Science ®Google Scholar
• Worobec AS, Metcalfe DD. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 2002;127:153-5
   PubMed Web of Science ®Google Scholar
• Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol 2009;129:2723-6
   PubMed Web of Science ®Google Scholar
• Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992;97:216-25
   PubMed Web of Science ®Google Scholar
• Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006;5:61-77
   PubMedGoogle Scholar
• Siebenhaar F, Fortsch A, Krause K, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013;68:949-52
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Groarke JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med 1979;90:769-71
   PubMed Web of Science ®Google Scholar
• Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004;350:735-6
   PubMed Web of Science ®Google Scholar
• Sancho-Chust JN, Chiner E, Camarasa A, Llombart M. Recent-onset bronchial asthma as a manifestation of systemic mastocytosis. J Investig Allergol Clin Immunol 2009;19:513-15
   PubMed Web of Science ®Google Scholar
• Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012;29:222-3
   PubMed Web of Science ®Google Scholar
• Rodriguez T, Pfeffer M, Levy BD, Castells M. Lipid mediators in cutaneous and systemic mastocytosis and the impact of 5-LO inhibition. J Allergy Clin Immunol 2011;127:AB132
   Web of Science ®Google Scholar
• Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009;88:122-4
   PubMed Web of Science ®Google Scholar
• Martin MW, O'Sullivan AJ, Gomperts BD. Inhibition by cromoglycate and some flavonoids of nucleoside diphosphate kinase and of exocytosis from permeabilized mast cells. Br J Pharmacol 1995;115:1080-6
   PubMed Web of Science ®Google Scholar
• Norris AA. Pharmacology of sodium cromoglycate. Clin Exp Allergy 1996;26(Suppl 4):5-7
   PubMedGoogle Scholar
• Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011;12:259-70
   PubMed Web of Science ®Google Scholar
• Vieira Dos SR, Magerl M, Martus P, et al. Topical sodium cromoglycate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2009;162:674-6
   PubMed Web of Science ®Google Scholar
• Edwards AM, Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep 2011; published online 29 June 2011, doi:10.1136/bcr.02.2011.3910
   Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:1550-1
   PubMed Web of Science ®Google Scholar
• Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012;108:383-4
   PubMed Web of Science ®Google Scholar
• Matito A, Blazquez-Goni C, Morgado JM, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 2013;111:425-6
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120:213-15
   PubMed Web of Science ®Google Scholar
• Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008;63:376-8
   PubMed Web of Science ®Google Scholar
• Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006;117:1203-12
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78
   PubMed Web of Science ®Google Scholar
• Krönauer C, Eberlein-König B, Ring J, Behrendt H. Influence of UVB, UVA and UVA1 irradiation on histamine release from human basophils and mast cells in vitro in the presence and absence of antioxidants. Photochem Photobiol 2003;77:531-4
   PubMed Web of Science ®Google Scholar
• Guhl S, Hartmann K, Tapkenhinrichs S, et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J Invest Dermatol 2003;121:837-44
   PubMed Web of Science ®Google Scholar
• Stege H, Schopf E, Ruzicka T, Krutmann J. High-dose UVA1 for urticaria pigmentosa. Lancet 1996;347:64
   PubMed Web of Science ®Google Scholar
• Smith ML, Orton PW, Chu H, Weston WL. Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 1990;7:251-5
   PubMed Web of Science ®Google Scholar
• Escribano L, García-Belmonte D, Hernández-González A, et al. Successful management of a case of diffuse cutaneous mastocytosis with recurrent anaphylactoid episodes and hypertension. J Allergy Clin Immunol 2004;113:S335
   Google Scholar
• Gobello T, Mazzanti C, Sordi D, et al. Medium-versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 2003;49:679-80
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2011;157:275-80
   PubMed Web of Science ®Google Scholar
• Gonzalez de Olano D, de la Hoz B, Nunez-Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37:1547-55
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Zanotti R, Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10:347-53
   PubMed Web of Science ®Google Scholar
• Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-32
   PubMed Web of Science ®Google Scholar
• Matito A, Bartolome-Zavala B, Alvarez-Twose I, et al. IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. Allergy 2009;65:1058-9
   PubMed Web of Science ®Google Scholar
• Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519-26
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009;64:1379-82
   PubMed Web of Science ®Google Scholar
• Niedoszytko M, de Monchy J, Van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009;64:1237-45
   PubMed Web of Science ®Google Scholar
• Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, et al. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011;3:637-51
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Gonzalez-De-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety and practical considerations. J Allergy Clin Immunol 2013;131:AB25
   Web of Science ®Google Scholar
• Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484-8
   PubMed Web of Science ®Google Scholar
• Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128:344-50
   PubMed Web of Science ®Google Scholar
• Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112:946-56
   PubMed Web of Science ®Google Scholar
• Rabenhorst A, Christopeit B, Leja S, et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 2013;132:1234-7
   PubMed Web of Science ®Google Scholar
• Lim AYN, Ostor AJK, Love S, Crisp AJ. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005;64:965-6
   PubMed Web of Science ®Google Scholar
• Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:1838-41
   PubMed Web of Science ®Google Scholar
• Alexander RR. Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. Acta Haematol 1985;74:108-10
   PubMed Web of Science ®Google Scholar
• Chen X, Regn S, Raffegerst S, et al. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol 2000;111:596-607
   PubMed Web of Science ®Google Scholar
• Borden EC, Wadler S. Interferons as biochemical modulators. J Clin Oncol 1996;14:2627-30
   PubMed Web of Science ®Google Scholar
• Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 2010;43:244-7
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Sperr W, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-41
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249-57
   PubMed Web of Science ®Google Scholar
• Lehmann T, Lammle B. IFNalpha treatment in systemic mastocytosis. Ann Hematol 1999;78:483-4
   PubMed Web of Science ®Google Scholar
• Lehmann T, Beyeler C, Lämmle B, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2b. Br J Rheumatol 1996;35:898-900
   PubMedGoogle Scholar
• Weide R, Ehlenz K, Lorenz W, et al. Successful treatment of osteoporosis in systemic: mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:41-3
   PubMed Web of Science ®Google Scholar
• Brunel V, Tadrist Z, Cailleres S, et al. Interferon alpha and pamidronate: a useful combination for osteoporosis in systemic mastocytosis. Presse Med 1998;27:64
   PubMed Web of Science ®Google Scholar
• Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-4
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:695-717
   PubMed Web of Science ®Google Scholar
• Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-9
   PubMed Web of Science ®Google Scholar
• Escribano L, Pérez de Oteyza J, Núñez R, Orfao A. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res 2002;26:1043-6
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-6
   PubMed Web of Science ®Google Scholar
• Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004;28:127-31
   PubMed Web of Science ®Google Scholar
• Bohm A, Sonneck K, Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010;38:744-55
   PubMed Web of Science ®Google Scholar
• Ma YS, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4
   PubMed Web of Science ®Google Scholar
• Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24
   PubMed Web of Science ®Google Scholar
• Elliott MA, Pardanani A, Li CY, Tefferi A. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. Leukemia 2004;18:1027-9
   PubMed Web of Science ®Google Scholar
• Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6
   PubMed Web of Science ®Google Scholar
• Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44
   PubMed Web of Science ®Google Scholar
• Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010;85:921-5
   PubMed Web of Science ®Google Scholar
• Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012;89:47-52
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-15
   PubMed Web of Science ®Google Scholar
• Gotlib J, Kluin-Nelemans HC, George TI, et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012;120
   Web of Science ®Google Scholar
• Gruson B, Lortholary O, Canioni D, et al. Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. Br J Haematol 2013;161:434-42
   PubMed Web of Science ®Google Scholar
• Lombardi C, Salmi A, Savio A, Passalacqua G. Localized eosinophilic ileitis with mastocytosis successfully treated with oral budesonide. Allergy 2007;62:1343-5
   PubMed Web of Science ®Google Scholar
• Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005;115:584-91
   PubMed Web of Science ®Google Scholar
• Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7
   PubMedGoogle Scholar
• Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 2009;124:625-36
   PubMed Web of Science ®Google Scholar
• Ring J, Grosber M, Mohrenschlager M, Brockow K. Anaphylaxis: acute treatment and management. Chem Immunol Allergy 2010;95:201-10
   PubMedGoogle Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101:4714-16
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
   PubMed Web of Science ®Google Scholar
• Zermati Y, De Sepulveda P, Féger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22:660-4
   PubMed Web of Science ®Google Scholar
• Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011;13:180-8
   PubMed Web of Science ®Google Scholar
• Kristensen T, Broesby-Olsen S, Vestergaard H, et al. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012;89:42-6
   PubMed Web of Science ®Google Scholar
• Pottier P, Planchon B, Grossi O. Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha. Rev Med Interne 2003;24:542-6
   PubMed Web of Science ®Google Scholar
• Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson cancer center experience. Am J Hematol 2004;77:209-14
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Vano-Galvan S, Sanchez-Munoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 2012;67:813-21
   PubMed Web of Science ®Google Scholar
• Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol 2013;131:AB116
   Web of Science ®Google Scholar
• Theoharides TC, Spanos C, Pang XZ, et al. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 1995;136:5745-50
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Perez-Somarriba J, Sainz-Costa T, et al. A 38 year old woman with hypotensive shock at the onset of menstruation: case outcome. BMJ Case Rep 2009;338:b247
   Google Scholar